Microchip (MCHP) sales ramp explained; Regeneron quick look

I have a new article at Seeking Alpha:

How Microchip Ramped Earnings With 8-Bit Devices

Another reason Microchip (MCHP) may be undervalued is the strength of its recent acquisitions. Unlike some companies, Microchip seems to be able to pay reasonable prices to acquire smaller semiconductor companies, and then both ramps their sales and increases margins. It also may incorporate technology from the acquisitions into SoC devices (System on Chip).

I have owned Microchip continuously since 2007. It pays a nice dividend and has increased nicely in price over the years.

This morning I listened to the Regeneron conference call. It looks like there is going to be a big profit ramp in the coming months from Eyelea, followed by the likely ramping of a new blockbuster for cholesterol control starting perhaps in the second half of 2015. There is more in the pipeline too. On the other hand the P/E ratio is high, so some pipeline success is figured in. I hope to write a more detailed report about Regeneron some day soon. REGN. I first bought REGN in June of this year. You can read my Regeneron Q2 2014 notes by following the link.